Ongoing clinical trials with BsAbs targeting BCMA in relapsed or refractory AL amyloidosis. Abbv-833, entetaming; d, day; dFLC, difference between involved and uninvolved serum free light chains; EOT, end of treatment; PI, proteasome inhibitor; q, every; SQ, subcutaneous administration; VGPR, very good partial response.